BR112017023437A2 - método para separação de proteína e outras impurezas de polissacarídeos capsulares microbianos - Google Patents

método para separação de proteína e outras impurezas de polissacarídeos capsulares microbianos

Info

Publication number
BR112017023437A2
BR112017023437A2 BR112017023437A BR112017023437A BR112017023437A2 BR 112017023437 A2 BR112017023437 A2 BR 112017023437A2 BR 112017023437 A BR112017023437 A BR 112017023437A BR 112017023437 A BR112017023437 A BR 112017023437A BR 112017023437 A2 BR112017023437 A2 BR 112017023437A2
Authority
BR
Brazil
Prior art keywords
impurities
capsular polysaccharides
separating protein
microbial capsular
microbial
Prior art date
Application number
BR112017023437A
Other languages
English (en)
Other versions
BR112017023437B1 (pt
Inventor
Charan Kantam
Datla Mahima
Venkateswara Reddy Muthyala
Dev Mantena Narender
Venkat Matur Ramesh
Babu Kandimalla Vivek
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of BR112017023437A2 publication Critical patent/BR112017023437A2/pt
Publication of BR112017023437B1 publication Critical patent/BR112017023437B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Sustainable Development (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a invenção se refere a um método para a remoção de proteína e outras impurezas de polissacarídeos capsulares microbianos. mais particularmente, a presente invenção se refere ao isolamento de polissacarídeos capsulares microbianos em forma pura após a remoção de proteína e outras impurezas.
BR112017023437-8A 2015-04-28 2016-04-25 Métodos para o isolamento de polissacarídeo capsular de bactérias e composição imunogênica BR112017023437B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2161CH2015 2015-04-28
IN2161/CHE/2015 2015-04-28
PCT/IN2016/000107 WO2016174683A1 (en) 2015-04-28 2016-04-25 Method for separation of protein and other impurities from microbial capsular polysaccharides

Publications (2)

Publication Number Publication Date
BR112017023437A2 true BR112017023437A2 (pt) 2018-07-31
BR112017023437B1 BR112017023437B1 (pt) 2022-03-22

Family

ID=56137482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023437-8A BR112017023437B1 (pt) 2015-04-28 2016-04-25 Métodos para o isolamento de polissacarídeo capsular de bactérias e composição imunogênica

Country Status (12)

Country Link
US (2) US10836839B2 (pt)
EP (1) EP3288983A1 (pt)
JP (1) JP6882193B2 (pt)
CN (1) CN107835821B (pt)
AU (1) AU2016254693B2 (pt)
BR (1) BR112017023437B1 (pt)
CA (1) CA2983708C (pt)
EA (1) EA201792366A1 (pt)
MX (1) MX2017013855A (pt)
SA (1) SA517390202B1 (pt)
WO (1) WO2016174683A1 (pt)
ZA (1) ZA201707454B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3506935T3 (fi) 2016-09-02 2024-04-17 Sanofi Pasteur Inc Neisseria meningitidis -rokote
EP3518965A1 (en) 2016-09-30 2019-08-07 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
BE1025162B9 (fr) * 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US20220390423A1 (en) 2019-10-01 2022-12-08 Biological E Limited Methods for quantification of carbohydrates
CN116693706A (zh) * 2022-02-24 2023-09-05 成都生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
EP1053021B1 (en) * 1998-02-05 2009-01-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
ES2396955T3 (es) * 2006-07-06 2013-03-01 Reliance Life Sciences Pvt., Ltd. Procedimiento para la purificación de ácido hialurónico de elevado peso molecular
WO2008045852A2 (en) 2006-10-10 2008-04-17 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
EP3626263A1 (en) * 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
CA2830879C (en) 2011-03-22 2018-10-30 Serum Institute Of India Ltd. A novel process for preparation of polysaccharides
CN103623401A (zh) 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
PE20161095A1 (es) * 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos

Also Published As

Publication number Publication date
US11680111B2 (en) 2023-06-20
EA201792366A1 (ru) 2018-03-30
JP6882193B2 (ja) 2021-06-02
CA2983708A1 (en) 2016-11-03
AU2016254693A1 (en) 2017-11-09
US20180155453A1 (en) 2018-06-07
CA2983708C (en) 2023-09-19
US10836839B2 (en) 2020-11-17
CN107835821A (zh) 2018-03-23
SA517390202B1 (ar) 2021-04-19
CN107835821B (zh) 2022-01-28
AU2016254693B2 (en) 2020-07-09
WO2016174683A1 (en) 2016-11-03
ZA201707454B (en) 2019-11-27
EP3288983A1 (en) 2018-03-07
US20210017300A1 (en) 2021-01-21
BR112017023437B1 (pt) 2022-03-22
MX2017013855A (es) 2018-03-15
JP2018514624A (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
BR112017023437A2 (pt) método para separação de proteína e outras impurezas de polissacarídeos capsulares microbianos
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
EP3291806A4 (en) Process to extract and purify delta-9-tetrahydrocannabinol
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
EP3256510A4 (en) Process and system for production of polypropiolactone
ZA201908038B (en) Method for removal of impurities from bacterial capsular polysaccharide based preparations
MY178852A (en) Process for separating a synthetic turf product
EP3287209A4 (en) PRODUCTION METHOD FOR Ni-BASED SUPER HEAT-RESISTANT ALLOY
GB201715306D0 (en) Methods, systems, and media for processing queries relating to presented media content
PH12016501515B1 (en) Method for producing vitamine e-enriched, especially tocotrienol-enriched, compositions from natural oils
EP3183978A4 (en) Production method for producing 3,5-dihydroxy-4-methoxybenzyl alcohol from oyster meat
MX2016006231A (es) Proceso de preparación de una grasa de sulfonato de calcio complejo.
EP3307810A4 (en) ORGANIC SOLVENT-BASED PROCESS FOR THE EXTRACTION OF EXTREMELY PURE LIGNIN, AND PRODUCTS COMPRISING LIGNIN
CL2015003432A1 (es) Método para la oxidación y separación de arsénico de soluciones de proceso y residuales.
PT3390517T (pt) Processo para a separação de borracha natural não hevea na forma sólida de soluções que a incluem
EA201690396A1 (ru) Производное ванкомицина, способ его получения и его применение
EP3235947A4 (en) Fabric bearing design and process for producing same
BR112015026703A2 (pt) revestimento alimentício artificial, método para a remoção e método para a fabricação do mesmo
PL3240887T3 (pl) Odmiana drożdży olejogennych, sposób jej otrzymywania i jej zastosowanie do wytwarzania lipidów
IN2013CH02496A (pt)
EP3352928A4 (en) SYSTEM AND METHOD FOR PRODUCING BIOFUEL
PL3134535T3 (pl) Sposób otrzymywania lipidów z biomasy z wykorzystaniem drobnoustrojów olejogennych
EP3196169A4 (en) METHOD FOR SEPARATING o/w EMULSION INTO OIL AND WATER, AND OIL/WATER SEPARATION AGENT FOR o/w EMULSION
EP3373917A4 (en) METHOD FOR RECOVERING RESIDUAL GEL MASS FROM SOFTGEL MANUFACTURING PROCESS
EP3345992A4 (en) METHOD FOR THE PRODUCTION OF MEAT, WHICH IS POSSIBLE TO REDUCE THE INGREDIENT OF SATURATED FATTY ACIDS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2016, OBSERVADAS AS CONDICOES LEGAIS.